Glucose-6-phosphatase dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in humans, affecting 400 million people worldwide and a high prevalence in persons of African, Middle Asian countries. The most common clinical manifestations are neonatal jaundice and acute hemolytic anemia, which is caused by the impairment of erythrocyte’s ability to remove harmful oxidative stress triggered by exogenous agents such as drugs, infection, or fava bean ingestion. Neonatal hyperbilirubinemia caused by glucose-6-phosphate dehydrogenase (G6PD) is strongly associated with mortality and long-term neurodevelopmental impairment. Aim:To determine a level of glucose-6-phosphate dehydrogenase in healthy neonates.The 76.5% of all participants (n=205) was assessed 4.36±1.15 Ug/Hb in normal reference range of G6PD other 23.5% (n=63) was 0.96±0.51 Ug/Hb with G6PD deficiency. In the both sex, 51.5% of male 0.88±0.46Ug/Hb (n=33) and 47.6%of female (n=30) 0.97±0.55Ug/Hb was assessed with G6PDdeficiency. Developing Jaundice period in number of 63 neonates with G6PD deficiency, 85.7% of neonates (n=54)was in 24-72 hours, 4% of neonates (n=3) was in 5-7 days and there is no sign of jaundice in 9% (n=6).Therefore neonates with G6PD deficiency, 53.9% (n=34)contiuned jaundice more than two weeks.G6PD deficiency was determined in male neonates (51.5%) more than female(47.6%). The 76.5% of all participants (n=205) was assessed 4.36±1.15 Ug/Hb in normal reference range of G6PD other 23.5% (n=63) of all participants was 0.96±0.51 Ug/Hb with G6PD deficiency. It shows that G6PD might be one potential risk of neonatal jaundice and hyperbilirubinemia in neonates in Mongolia.

BACKGROUND: Cardiovascular diseases (CVDs) account for >17 million deaths globally each year and this figure is expected to grow to 23.6 million by 2030. According to the WHO report, one-third of ischemic heart disease is attributable to high cholesterol. There have been some claims that the atherogenic index of plasma (AIP), which is the logarithmic transformation of the just-mentioned ratio (TG/HDL-C), could be used as a significant predictor of atherosclerosis, and CVD as well. Thus, we aimed to study the relationship between AIP and cardiovascular risk factors. METHODS: The cross-sectional hospital based study was conducted including 117 participants aged between 40-72 years old without cardiovascular symptoms were recruited from Second General Hospital. After filled consent form, participants’ habits of smoking, alcohol usage, obesity, arterial hypertension and sedentary lifestyle were assessed through a structured questionnaire and physical examination. By using fully automated open-system analyzer, determinations of total cholesterol, triglycerides, low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C) three times and glucose twice were performed simultaneously and then their averages were calculated. At least one abnormal lipid level was considered as “dyslipidemia”. The atherogenic index of plasma (AIP) was calculated as the logarithmically transformed ratio of molar concentrations of TG to HDL-C. Statistical analysis was performed using SPSS 22. RESULTS: Of total 117 participants ranging 40-72 years old, 45.3% were male and 54.7% were female with mean age 53.6±0.79. Regarding cardiovascular risk factors, 63.8% were physically inactive, 32.48% were smokers, 47% were alcohol user, 48% were hypertensive, and 18.26% were diabetic. The mean values plus standard error of lipid components were 195.5±6.09 mg/dL in cholesterol, 181.25±27.36 mg/dL in triglycerides, 60.6±1.39 mg/dL in HDL-C, 138.5±3.74 mg/dL in LDL-C, 6.27±0.26 mmol/L in fasting glucose. The dyslipidemia was detected in 54.7% of total participants and mean level of AIP was 0.33±0.03 (min=-0.52; max=1.51). The mean levels of 10 year and lifetime risk were 6.25±0.63% (min=0.2; max=33.5) and 43±1.53% (min=7.5; max=69), respectively. AIP had weak correlations with gender, smoking, anti-hypertensive drug usage, aspirin usage, 10 year and lifetime risks of CVD, hypertension, fasting glucose, body mass index, and dyslipidemia (0.2

Introduction: Scutellaria baicalensis Georgi, which is used in traditional medicine, has the ability to remove blood-drying heat. Chiazospermum erectum Bernh. has the ability to relieve typhoid fever and poison fever. Carthamus tinctorius L. has antiseptic, analgesic and anti-toxic properties. Saussurea amara L. has bactericidal, anti-infective, and anti-inflammatory properties. Researchers found that the Hepaclin-4 recipe has antioxidant, membrane-strengthening, liver-protective, necrosis-preventing, detoxification, and peroxidation product accumulation-reducing properties. Therefore, extracting the granular medicine form from the concentrated extract containing the Hepaclin-4 formulation is the basis of our research work. Goal: To obtain the granular medicine form from the concentrated extract containing ingredients of the Hepaclin-4 recipe. Materials and Methods: The research was carried out with the support of the Institute of Pharmaceutical Research and the University of Pharmaceutical Sciences. The raw materials for the Hepaclin-4 formula were extracted by remaceration with water, 40% ethanol, and 70% ethanol (1:10 ratio). Six types of granules were extracted from the concentrated extract using several excipients by the wet granulation method, and the pouring weight and flowability were determined. Results: The quality index of the concentrated extract of the Hepaclin-4 recipe complies with the standards outlined in the 11th Pharmacopoeia of the National Pharmacopoeia of Mongolia. In qualitative analysis of total flavonoid, spots were detected at the same level as standard quercetin (Rf=0.88) and rutin (Rf=0.4), indicating the presence of flavonoids. According to the results of the above research, lactose was found to be the suitable filler for extracting granules, and starch at 8% was identified as the appropriate binding agent from the concentrated extract of the Hepaclin-4 formula. Conclusion It was found suitable to select 8% lactose as a filler and starch as a binding agent from the concentrated extract of the Hepaclin-4 formula and obtain a granule drug form using the wet granulation method.